Kiora Pharmaceuticals (NASDAQ:KPRX) Given New $10.00 Price Target at HC Wainwright

Kiora Pharmaceuticals (NASDAQ:KPRX) had its price objective upped by HC Wainwright from $2.00 to $10.00 in a report issued on Tuesday morning, Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Kiora Pharmaceuticals’ Q2 2024 earnings at ($0.95) EPS, Q3 2024 earnings at ($0.66) EPS, Q4 2024 earnings at ($0.65) EPS, FY2024 earnings at $1.31 EPS, Q1 2025 earnings at ($0.67) EPS, Q2 2025 earnings at ($0.66) EPS, Q3 2025 earnings at ($0.67) EPS, Q4 2025 earnings at ($0.67) EPS and FY2025 earnings at ($2.66) EPS.

Separately, Maxim Group raised shares of Kiora Pharmaceuticals to a strong-buy rating in a research note on Thursday, June 13th.

Kiora Pharmaceuticals Stock Up 0.2 %

NASDAQ:KPRX opened at $4.70 on Tuesday. Kiora Pharmaceuticals has a 52-week low of $3.60 and a 52-week high of $8.98. The stock has a fifty day simple moving average of $5.22 and a 200-day simple moving average of $5.30.

Kiora Pharmaceuticals (NASDAQ:KPRX) last released its quarterly earnings results on Friday, May 10th. The company reported $3.42 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.58 by ($2.16). The firm had revenue of $16.00 million during the quarter, compared to analyst estimates of $16.00 million. As a group, research analysts predict that Kiora Pharmaceuticals will post 0.97 EPS for the current year.

Insider Activity at Kiora Pharmaceuticals

In other news, Director Erin Parsons bought 5,260 shares of the business’s stock in a transaction that occurred on Thursday, June 13th. The stock was purchased at an average price of $4.88 per share, with a total value of $25,668.80. Following the purchase, the director now owns 5,260 shares of the company’s stock, valued at approximately $25,668.80. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last quarter, insiders bought 9,791 shares of company stock valued at $48,764. 0.94% of the stock is owned by insiders.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Kiora Pharmaceuticals stock. Rosalind Advisors Inc. acquired a new stake in shares of Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 2,300,000 shares of the company’s stock, valued at approximately $1,624,000. Kiora Pharmaceuticals comprises approximately 1.5% of Rosalind Advisors Inc.’s portfolio, making the stock its 22nd biggest holding. Rosalind Advisors Inc. owned about 8.76% of Kiora Pharmaceuticals at the end of the most recent quarter. 76.97% of the stock is currently owned by institutional investors.

About Kiora Pharmaceuticals

Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.